• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

tetano

Editor, Senior Moderator
Antiviral Res. 2017 May 23. pii: S0166-3542(17)30009-8. doi: 10.1016/j.antiviral.2017.05.009. [Epub ahead of print]
[h=1]Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine.[/h] Giarola-Silva S[SUP]1[/SUP], Coelho-Dos-Reis JGA[SUP]1[/SUP], Mour?o MM[SUP]2[/SUP], Campi-Azevedo AC[SUP]1[/SUP], Nakagaki Silva EE[SUP]2[/SUP], Luiza-Silva M[SUP]3[/SUP], Martins MA[SUP]1[/SUP], de Oliveira Silveira Cassette AC[SUP]1[/SUP], Batista MA[SUP]1[/SUP], Peruhype-Magalh?es V[SUP]1[/SUP], do Valle Antonelli LR[SUP]4[/SUP], Leite Ribeiro JG[SUP]5[/SUP], El?i-Santos SM[SUP]6[/SUP], Machado AV[SUP]7[/SUP], Teixeira-Carvalho A[SUP]1[/SUP], Martins-Filho OA[SUP]1[/SUP], Ara?jo MSS[SUP]8[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4[SUP]+[/SUP], CD8[SUP]+[/SUP] T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tlr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,IL-6,IL-1β,IL-12,IL-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-α/IL-12/IFN-γ axis derived from NK-cells, CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cells along with promiscuous production of IL-4/IL-5/IL-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-α and IL-4, with late IL-10 production by CD8[SUP]+[/SUP] T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4[SUP]+[/SUP]/CD8[SUP]+[/SUP] T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity.
Copyright ? 2017. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] AS03 adjuvant; Biomarker signature; H1N1 vaccine; Immune response

PMID: 28549970 DOI: 10.1016/j.antiviral.2017.05.009
 
Back
Top Bottom